Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells
- 8 September 1999
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 26 (1) , 53-61
- https://doi.org/10.1002/(sici)1098-2744(199909)26:1<53::aid-mc7>3.0.co;2-z
Abstract
To understand the expression and role of thyroid hormone nuclear receptors (TRs) in hepatocarcinogenesis, we characterized the TRs in 16 human hepatocellular carcinoma (HCC) specimens. The full‐length cDNAs for the two TR subtypes, α1 and β1, were cloned from several tumors by reverse transcription–polymerase chain reaction. Southern blot analysis indicated that, in addition to the full‐length cDNA, truncated TRα1 and TRβ1 cDNAs were present in nine tumors (53%). In addition, point mutations detected by the mismatch RNase cleavage assay in TRα1 and TRβ1 were found in 65% and 76% of the tumors, respectively. The mutations were confirmed by DNA sequencing. Interestingly, most of the TRα1 mutations were in amino acid codons 209–228 and 245–256, two hot‐spots in HCC patients. However, no hot‐spot was detected in TRβ1. The expression of TRα1 and TRβ1 proteins was determined in the tissue extracts by western blotting. TR β1 protein was expressed or elevated in 10 tumors but not in normal livers, whereas the expression of TRα1 was variable among tumors. The mutant TR proteins were translated in vitro, and their hormone‐ and DNA‐binding activities were evaluated. Abnormal binding to the thyroid hormone response elements was observed. The proteins' DNA binding activity was either partially impaired or completely lost. The high prevalence of TR mutations found in the tumors of patients with hepatocellular carcinoma suggests that mutant TRs could play an important role in liver carcinogenesis. Mol. Carcinog. 26:53–61, 1999.This publication has 28 references indexed in Scilit:
- Dominant Negative Activity of Mutant Thyroid Hormone α1 Receptors from Patients with Hepatocellular Carcinoma*Endocrinology, 1997
- Tumor Suppressor p53 Is a Negative Regulator in Thyroid Hormone Receptor Signaling PathwaysJournal of Biological Chemistry, 1997
- Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line.Endocrinology, 1996
- Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53.Proceedings of the National Academy of Sciences, 1996
- New insights into the structure and function of the thyroid hormone receptorJournal of Biomedical Science, 1995
- Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA.The EMBO Journal, 1994
- Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA.Published by Elsevier ,1994
- Current pathogenetic and molecular concepts in viral liver carcinogenesisVirchows Archiv B Cell Pathology Including Molecular Pathology, 1993
- Hormones, growth factors and oncogenes in the evaluation of risk for hepatocellular carcinomasEuropean Journal Of Cancer Prevention, 1992
- Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA:DNA DuplexesScience, 1985